A rumor regarding Crispr Therapeutics (CRSP) was highlighted again in Ben Harrington’s M&A-focused Betaville blog, contacts tell The Fly. The blog also highlighted rumors regarding Crispr Therapeutics previously on December 1, 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Cathie Wood Loads Up on Biotech Stocks While Trimming Several Tech Positions
- Crispr Therapeutics price target raised to $33 from $32 at Morgan Stanley
- IHI, IHE, ARKG: Specialty Healthcare ETFs Can Help Boost a Portfolio
- Crispr Therapeutics price target lowered to $67 from $69 at JPMorgan
- Crispr Therapeutics price target raised to $80 from $77 at Citi